Therapeutically, bioprinting will likely achieve clinical success first with the least complex tissues (such as skin) that are already being delivered, even if they are not yet shelf ready. “In the more distant future, with further progress in largescale cell culture, bioprocess engineering, and genetic strategies, it is possible that we will be able to design specific printable living structures that are not even conceivable today. Tissues printed with gene-edited cells from the diseased patient to achieve a normal endpoint or combination of extended bioprinted tissue units functionally interconnected similarly to that in the human body are examples that could lead to unforeseen progress in regenerative medicine.”1
“Bioprinting offers many promising opportunities. However, patience and perseverance are needed to realize the full potential of the technology.”1
Dr. Atala is the Editor‐in‐Chief of Stem Cells Translational Medicine and Director of the Wake Forest Institute for Regenerative Medicine, and the W. Boyce Professor and Chair of Urology at Wake Forest University.
Dr. Atala is a practicing surgeon and a researcher in the area of regenerative medicine. His work focuses on growing human cells, tissues and organs. Dr. Atala heads a team of over 450 physicians and researchers. Over twelve applications of technologies developed in Dr. Atala’s laboratory have been used clinically.
Dr. Forgacs is a physicist turned tissue engineer turned innovator and entrepreneur. He received his physics training at the Eötvös Loránd University, Budapest, Hungary. His academic affiliations include the George Vineyard Chair in Biophysics at the University of Missouri-Columbia and the Chanderna-Stirkey Chair in Theoretical Physics at Clarkson University, where he also served as the Director of the Shipley Innovation Center. He is the scientific founder of Organovo, Inc., Modern Meadow, Inc., and Fork & Goode, Inc., and serves as the Chief Scientific Officer of the latter. He is a pioneer in methods of building living structures, in particular by bioprinting. The technologies he has developed have been applied to drug development and testing and the engineering of biomaterials of animal origin, such as leather in an environmentally friendly and ethically conscious manner. Dr. Forgacs has been recognized by numerous awards. In particular, he is a member of the National Academy of Innovators and was named as one of the “100 most innovative people in business in 2010” by FastCompany.
- Anthony Atala, Gabor Forgacs. Three-Dimensional Bioprinting in Regenerative Medicine: Reality, Hype, and Future. STEM CELLS TRANSLATIONAL MEDICINE 2019;8:744–745